Pancreatic Cancer Drugs Market Analysis | 2021-2026

Market Insights

"The global pancreatic cancer drug market is likely to rebound at a significant CAGR of 8.1%."

Pancreatic cancer is defined as a kind of cancer that happens within the tissues of the pancreas. The pancreas is found behind the stomach and it aids in digestion by producing enzymes needed by the body to digest fats, proteins, and carbohydrates. Supported type, pancreatic cancer may be categorized as Abraxane (paclitaxel albumin-stabilized nanoparticle formulation), Afinitor (everolimus), erlotinib hydrochloride, everolimus, and 5-fu (fluorouracil injection) among others.

Want to get a free sample? Register Here

Market Dynamics:

The growth of the pancreatic cancer drugs market is primarily driven by:

• Rising incidences of pancreatic cancer due to obesity, high consumption of alcohol, and smoking.
• Expanding the geriatric population is likely to drive the market growth further. It can also occur as a result of a family history of pancreatitis mutation.
• Increasing investment in research and development activities to develop advanced diagnostic solutions is likely to create lucrative opportunities for the players operating in the global pancreatic cancer drugs market in the coming years. However, the high treatment cost is likely to affect the growth of the pancreatic cancer diagnostic market.

The COVID-19 outbreak has moderately affected the pancreatic cancer drugs industry. The virus outbreak has turned the lives of people worldwide, with the number of cases increasing rapidly. The COVID-19 crisis has reduced the number of visits to ophthalmology clinics and eye surgeries were postponed to curb the spread of the virus, thus affecting market growth amid the pandemic.

The main challenges in the pancreatic cancer drugs market are the aggressiveness of pancreatic cancer, survival rates, precision medicine, reliance on traditional chemotherapies with limited effectiveness, and the elderly population precluding eligibility for curative surgery.

Key Players

Key players operating in the pancreatic cancer drugs market are:

• Eli Lilly and Company (US)
• Celgene Corporation (US)
• F. Hoffmann-La Roche AG (Switzerland)
• Novartis International AG (Switzerland)
• Clovis Oncology (US)
• Amgen Inc. (US)
• The Merck Group (Germany)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Pfizer Inc. (US)
• PharmaCyte Biotech, Inc. (US).

Segment Analysis

End-User Insights

"The hospital segment accounted for the largest market share."

The market has been bifurcated into hospitals and clinics. The hospitals segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period. The segment can be attributed to the presence of established infrastructure and skilled staff.

Regional Trends

"The North American market accounted for the largest market share."

The North American market accounted for the largest market share in 2020 and is projected to grow at a robust CAGR during the review period. This can be attributed to the growing emphasis on the adoption of advanced diagnostic solutions in the healthcare industry coupled with the presence of key market players such as Eli Lilly and Company (US) and Celgene Corporation (US). The market growth in Asia-Pacific is expected to be driven by an increasing number of people suffering from pancreatic cancer.

Want to get a free sample? Register Here

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into market dynamics and will enable strategic decision-making for existing market players as well as those willing to enter the market.

What deliverables will you get in this report?

This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.

The market is segmented into the following categories:

By Drug Type

• Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
• Afinitor (Everolimus)
• Erlotinib Hydrochloride
• Everolimus
• 5-FU (Fluorouracil Injection)
• Fluorouracil Injection
• Gemcitabine Hydrochloride
• Others

By Cancer Type 

• Endocrine Pancreatic Cancer
• Exocrine Pancreatic Cancer

By End-User Type 

• Hospitals
• Clinics

By Region

• North America
• Asia-Pacific
• Europe
• Rest of the World

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].